MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
ImmuCell Corporation DSO Ratio 2011-2026 | ICCC
Annual DSO Ratio ImmuCell Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 41 | 41.2 | 43.8 | 42.6 | 42.7 | 44.6 | 47.4 | 52.3 | 43.5 | 26.9 | 48.3 | 38.4 | 41.4 | 27.4 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 52.3 | 26.9 | 41.5 |
Quarterly DSO Ratio ImmuCell Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 40.9 | 40.5 | 40.2 | - | 32.3 | 38.1 | 30.2 | - | 28.4 | 46.4 | 51 | - | 29.6 | 48 | 40.7 | - | 39.6 | 44.6 | 46.5 | - | 44 | 55.3 | 10.2 | - | 50.3 | 55.1 | 26.6 | - | 39.5 | 28.2 | 36 | - | 35.8 | 44.8 | 25.8 | - | 627 | 273 | 493 | - | 416 | 222 | 404 | - | 318 | 421 | 575 | - | 188 | 258 | 511 | - | 237 | 393 | - | - | 148 | 227 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 627 | 10.2 | 157 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
258 | $ 209.63 | -0.71 % | $ 371 B |  USA |
 |
Verastem
VSTM
|
38.5 | $ 4.99 | -5.77 % | $ 346 M | USA |
 |
VistaGen Therapeutics
VTGN
|
28.9 | $ 0.57 | -5.85 % | $ 17.6 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Voyager Therapeutics
VYGR
|
14.8 | $ 3.96 | -4.24 % | $ 232 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
2.47 | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Avid Bioservices
CDMO
|
45.6 | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
60.7 | $ 12.36 | -11.46 % | $ 1.88 B | USA |
 |
Wave Life Sciences Ltd.
WVE
|
11.5 | $ 6.39 | 3.06 % | $ 1.08 B |  Singapore |
 |
Xenetic Biosciences
XBIO
|
365 | $ 2.78 | -0.71 % | $ 4.73 M | USA |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
XBiotech
XBIT
|
40.8 | $ 2.27 | -1.73 % | $ 69.2 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
72.6 | $ 54.44 | -1.96 % | $ 4.24 B | Canada |
 |
Xeris Pharmaceuticals
XERS
|
57.2 | $ 5.41 | -2.87 % | $ 868 M | USA |
 |
X4 Pharmaceuticals
XFOR
|
46.1 | $ 4.07 | -5.57 % | $ 172 M | USA |
 |
Xencor
XNCR
|
131 | $ 11.4 | -7.43 % | $ 846 M | USA |
 |
XOMA Corporation
XOMA
|
23.6 | $ 29.93 | -1.97 % | $ 362 M | USA |
 |
22nd Century Group
XXII
|
54.9 | $ 2.41 | -18.03 % | $ 444 K | USA |
 |
BioDelivery Sciences International
BDSI
|
115 | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | USA |